Belgium
As of 05/20/2025, Oxurion NV's market capitalization has reached $417,921.43. According to our data, Oxurion NV is the 48320th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 417,921.43 |
| Revenue (ttm) | 3,383.13 |
| Net Income (ttm) | 134,197.49 |
| Shares Out | 6.16 M |
| EPS (ttm) | 0.11 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/19/2025 |
| Date | Market Cap | Change (%) |
|---|---|---|
| 05/20/2025 | €370,593 | -46.32% |
| 12/31/2024 | €766,134 | -73.79% |
| 12/29/2023 | €2.92 M | -62.57% |
| 12/30/2022 | €7.81 M | -88.99% |
| 12/31/2021 | €70.93 M | -27.49% |
| 12/31/2020 | €97.83 M |
Oxurion NV is a biopharmaceutical company dedicated to developing innovative treatments to prevent blindness and preserve vision.
| Country or region | Belgium |
| Founded | 1991 |
| IPO Date | n/a |
| Employees | 11 |
| CEO | Pascal Ghoson |
| Sector | Healthcare |
| Industry | Biotechnology |
| Address |
Gaston Geenslaan 1 Leuven, 3001 Belgium |
| Website | https://www.oxurion.com |
